Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups

[1]  C. Rubio,et al.  Retroperitoneal soft-tissue sarcomas: Radiotherapy experience from a tertiary cancer center and review of current evidence. , 2020, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[2]  J. Blay,et al.  Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. , 2020, JAMA oncology.

[3]  S. Dry,et al.  Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas , 2018, American journal of clinical oncology.

[4]  P Reichardt,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Robin L. Jones,et al.  The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk , 2018, JAMA oncology.

[6]  S. George,et al.  Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma , 2018, JAMA oncology.

[7]  A. Gronchi.  Towards the standard use of (neo)adjuvant chemotherapy in selected localised soft tissue sarcoma at high risk of relapse: are we finally getting there? , 2018, European journal of cancer.

[8]  D. Campanacci,et al.  Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma , 2018, Tumori.

[9]  B. Dickson,et al.  Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Blay,et al.  Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. , 2017, The Lancet. Oncology.

[11]  R. Benjamin.  Adjuvant and Neoadjuvant Chemotherapy for Soft Tissue Sarcomas: A Personal Point of View , 2017, Tumori.

[12]  L. Lévy,et al.  First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas , 2016, Clinical Cancer Research.

[13]  G. Rauch,et al.  Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03) , 2016, Radiation oncology.

[14]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  Peter F Thall,et al.  Phase 1 adaptive dose‐finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high‐risk extremity and trunk soft tissue sarcoma , 2015, Cancer.

[16]  S. Sleijfer,et al.  A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities , 2015, Acta oncologica.

[17]  Chin-Shang Li,et al.  Phase I Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity , 2014, Annals of Surgical Oncology.

[18]  A. D. Dei Tos,et al.  Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  A. D. Dei Tos,et al.  Tumor response assessment by modified Choi criteria in localized high‐risk soft tissue sarcoma treated with chemotherapy , 2012, Cancer.

[20]  J. Blay,et al.  Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D. Ettinger,et al.  Long‐term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high‐risk, high‐grade, soft tissue sarcomas of the extremities and body wall , 2010, Cancer.

[22]  L. Mariani,et al.  Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution: Local Control Directly Impacts Survival , 2010, Annals of surgery.

[23]  L. White,et al.  Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma , 2009, Cancer.

[24]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[25]  V. Torri,et al.  High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. , 2009, Radiology.

[26]  R. Sánchez-Prieto,et al.  In vitro radiosensitisation by trabectedin in human cancer cell lines. , 2008, European journal of cancer.

[27]  Robin L. Jones,et al.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.

[28]  L. Mariani,et al.  Myxoid/round cell and pleomorphic liposarcomas , 2007, Cancer.

[29]  F. Grosso,et al.  Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. , 2006, European journal of cancer.

[30]  Robin L. Jones,et al.  Differential sensitivity of liposarcoma subtypes to chemotherapy. , 2005, European journal of cancer.

[31]  Peter F Thall,et al.  Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Vermorken,et al.  In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects , 2003, British Journal of Cancer.

[33]  M. Ladanyi,et al.  Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  M. Höglund,et al.  Fusion of the EWS and CHOP genes in myxoid liposarcoma. , 1996, Oncogene.

[35]  H. Burstein,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[36]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[37]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[38]  J. Crielaard,et al.  [Myxoid liposarcoma]. , 2009, Revue medicale de Liege.